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Karyotype is a powerful prognostic factor for complete remission (CR) and overall survival (OS) in acute
myelogenous leukemia (AML). Adverse-risk karyotype AML is now treated with intensive chemotherapy
followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) to overcome relapse. We
attempted to stratify patients with this disease using a combination of known factors. We evaluated clinical
correlates in 211 adults with AML and adverse-risk karyotypes. We divided the patients into several sub-
groups based on the number of chromosomal aberrations (NCAs), normal karyotype (NK) mosaicism, and
monosomal karyotype (MK) status. CR rates and survival outcomes were compared among the subgroups,
and the relapse rate was calculated in the allo-HSCT subgroup. The cutoff of NCA 5 showed the worst OS
(P < .001) compared with NCA 3 or NCA 4 even after allo-HSCT. NK mosaicism signiﬁcantly improved OS in
both the NCA <5 (P ¼ .024) and NCA 5 (P ¼ .030) subgroups, but after allo-HSCT, it showed a favorable effect
only in the NCA <5 subgroup. MK showed worse OS (P ¼ .041), but there was no signiﬁcantly worse effect
after allo-HSCT compared with non-MK. Finally, we stratiﬁed patients into 4 subgroups, NCA 5 and NCA <5
with and without NK mosaicism. The most favorable OS and lower relapse rate after allo-HSCT were achieved
by the NCA <5 with NK mosaicism subgroup, and the NCA 5 without NK mosaicism subgroup showed the
worst prognosis in both entire group and allo-HSCT subgroup analysis. This study reveals that the combi-
nation of NCA and NK mosaicism may predict survival outcomes accurately, and suggests that novel treat-
ment strategies for highly adverse-risk group AML should be tailored in the future.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Numerous trials have stratiﬁed patients by karyotype into
several risk groups that more accurately predict the prog-
nosis of adult acute myelogenous leukemia (AML) and have
developed risk-adapted treatment strategies [1-6]. In addi-
tion, in the case of adverse-risk karyotype groups, several
reports have stratiﬁed combinatorial analysis using several
different risk factors. Although many different cytogenetic
classiﬁcations for adult AML are used at present, assignment
to the adverse-risk group is largely concordant and generally
includes abnormalities of 3q [ie, inv(3q), t(3;3) [7], 5q/-5,
7q/-7, abn(17p), t(6;9), and 11q23, except t(9;11)] and com-
plex karyotype (CK) status [1-6]. Although these single
adverse genetic abnormalities are well characterized, more
than one-half of the cases are accompanied by multiple
chromosomal abnormalities and are termed CK when 3 or
more aberrations are included. However, the signiﬁcant
number of chromosomal aberrations (NCAs; ie, 3 [1-3], 4edgments on page 87.
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13.10.015[4], or 5 [8]) for deﬁning the poor prognosis of CK remains
to be deﬁnitively determined.
The concepts of monosomal karyotype (MK) and normal
karyotype (NK) mosaicism, termed residual normal meta-
phases in clonal abnormality, have been considered in adult
AML cytogenetics at diagnosis. MK was ﬁrst introduced by
Breems et al. [9] and identiﬁed as associated with extremely
poor survival outcome (4% 4-yr overall survival [OS]), with
other studies reporting similar results [9-12]. In the case of
NK mosaicism, previous studies have shown that patients
with adverse-risk karyotype AML (ie, monosomy 5 and 7 or
MK) and residual normal metaphases at diagnosis had better
outcomes than those without normal metaphases [13,14]. In
a recent study, our group analyzed adult patients with AML
and adverse-risk karyotype treated by allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) according to the
presence of NKmosaicism at diagnosis [15]. Our data indicate
that NK mosaicism is a favorable factor for superior OS and
lower incidence of relapse after allo-HSCT in adult AML with
adverse-risk karyotype [15].
We sought to evaluate the prognostic impact of a com-
bination of the aforementioned components to identify a
new, more accurate deﬁnition for the highest-risk adult AML
karyotypes, which may help identify patients with these
karyotypes who might beneﬁt from allo-HSCT. We used NCA
and the combination of MK and NK mosaicism status forTransplantation.
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risk karyotype.
METHODS
Patients and Cytogenetic Analysis
This study was approved by the Catholic Medical Center’s Institutional
Review Board. A total of 1659 patients (age range, 18 to 92 yr) from the
Catholic Medical Center’s Department of Hematology database between
April 2001 and March 2012 were evaluated to identify patients with adult
AML karyotypes. Forty-nine patients with secondary AML and 22 patients
with therapy-related AML were identiﬁed, 18 of whom had an adverse-risk
karyotype. We excluded these 71 patients and focused on the 1588 patients
with de novo AML. All cytogenetic samples were bone marrow (BM) cells,
and analysis was performed on at least 20 metaphases by the GTG banding
method after 24/48 h of unsynchronized culture. The International System
for Cytogenetic Nomenclature [16] and National Comprehensive Cancer
Network [5] 2012 guidelines were used for classiﬁcation purposes.
We could not assess the karyotype results for 46 of the 1588 patients
with de novo AML (2.9%) owing to a lack of properly evaluable metaphases.
The 1542 that could be evaluated included 620 (39.0%) with a normal kar-
yotype, 213 (13.4%) with an unclassiﬁed abnormal karyotype, 184 (11.6%)
with t(8;21), 163 (10.3%) with t(15;17), 65 (4.1%) with inv(16) or t(16;16), 58
(3.6%) with trisomy 8, 12 (0.8%) with t(9;11), and 16 (1.0%) with t(9;22)e
Philadelphia (Ph)-positive chromosome. We excluded all of these patients,
and enrolled 211 patients (13.3%) with a median age of 50 yr (range, 18 to
85 yr) for adverse-risk karyotype analysis. The median follow-up duration
for survivors was 45.6 mo (range, 6.4 to 123.6 mo). We excluded 16 patients
with t(9;22), even those these patients are classiﬁed as an adverse-risk
group according to the National Comprehensive Cancer Network guide-
lines, because of the risk of misdiagnosis with myeloid blastic phase of
chronic myelogenous leukemia owing to ambiguous distinctions. Some
previously published guidelines did not include t(9;22) in classiﬁcation of
AML karyotypes [17].
An abnormality was considered clonal and mentioned in the karyotype
when at least 2 metaphases had the same aberration in cases of a structural
abnormality or an extra chromosome. The following abnormalities were
scored for each chromosome: loss of a chromosome (monosomy), extra copy
of a chromosome (trisomy or tetrasomy), structural cytogenetic abnormal-
ities (deletion of part of a chromosome, inversion within a chromosome,
translocation between chromosomes, or addition of chromosomalmaterial),
marker chromosomes, and ring chromosomes. We used 1 copy of normal
metaphase as the determinant of a NKmosaicism [15,18]. MKwas deﬁned as
multiple (ie, 2) autosomal monosomies or 1 autosomal monosomy in
combination with at least 1 structural chromosomal abnormality [9]. We
used 3 copies of cells including monosomies as the determinant of a clone.Table 1
CR Rate and Treatment Outcomes of Patients with AML and an Adverse-Risk Karyo
Diagnosis
NK Mosaicism (þ)
n CR, n (%) 3-yr OS,
Total cohort (n ¼ 211) 119 72 (60.5) 26
Age (median, 50 yr; range, 18-85 yr)
<50 yr (n ¼ 105) 61 50 (81.9) 36
50 yr (n ¼ 106) 58 22 (37.9) 16
Sex
Male (n ¼ 128) 67 38 (56.7) 20
Female (n ¼ 93) 52 34 (65.4) 33
Karyotype subgroup
NCA 5 (n ¼ 73) 42 21 (50.0) 17
NCA <5 (n ¼ 138) 77 51 (66.2) 31
NCA 3/4 (n ¼ 46) 28 20 (71.5) 36
NCA 3 (n ¼ 119) 70 41 (58.6) 25
CKþMKþ (n ¼ 53) 32 18 (58.2) 25
CKþMK (n ¼ 66) 38 23 (60.5) 25
NCA <3 (n ¼ 92) 49 31 (63.3) 28
Inv(3), t(3;3) (n ¼ 16) 7 2 (28.6) 0
Abnormal 5q/5 (n ¼ 10) 6 5 (83.3) 42
Abnormal 7q/7 (n ¼ 23) 16 7 (43.8) 22
11q23 (n ¼ 27) 11 9 (81.8) 46
t(6;9) (n ¼ 15) 9 6 (66.7) 22
CK MKþ (n ¼ 6) 5 2 (40.0) 0
CK MK (n ¼ 86) 44 29 (65.9) 31
MKþ (total, n ¼ 59) 37 20 (54.1) 22
CR includes incomplete CR (BM CR without complete blood count recovery, includ
* P < .05.Stratiﬁcation of Adverse-Risk Karyotype
We divided the patients into various subgroups according to NCA and
whether MK or NK mosaicism was combined or not, then compared the
treatment outcomes among the subgroups. First, to determine the appro-
priate cutoff, we evaluated NCA at the 3, 4, and 5 levels. We deﬁned CK as3
abnormal chromosomal aberrations and analyzed outcomes in 4 designated
subgroups: CKþMKþ, CKþMK, CKMKþ, and CKMK. We also created
subgroups combining MK status with NCA 5 or <5. Next, based on NCA
with NK mosaicism, we evaluated treatment outcomes in 4 other sub-
groups: subgroup 1, NCA <5 with NK mosaicism; subgroup 2, NCA <5
without NK mosaicism; subgroup 3, NCA 5 with NK mosaicism; and
subgroup 4, NCA 5 without NK mosaicism.Treatment Courses
Of the 211 patients, 41 opted for conservative treatment, and 170 were
treated with various induction chemotherapy regimens. Among these 170
patients, 109 (64.1%) patients were treated with 3 þ 7 idarubicin (IDA) plus
N4-behenoyl-1-b-D-arabinofuranosyl cytosine (BHAC) as remission induc-
tion chemotherapy. IDAwas administered daily at a dose of 12 mg/m2 i.v. for
3 consecutive days, and BHAC was administered daily at 300 mg/m2 for 7
consecutive days [19]. Twenty-ﬁve patients (14.7%) were treated with
3þ 7IDA plus cytosine arabinoside (ARA-C) at a dose of 100mg/m2. Twenty-
three elderly patients (13.5%) with a Eastern Cooperative Oncology Group
performance status of 2 [20] were treated with several doses of abbreviated-
schedule induction chemotherapy, and 13 elderly patients (7.6%) with sig-
niﬁcant comorbidity were treated with modiﬁed low-dose ARA-C (20 mg/
m2 every 12 h) combined with oral etoposide, 100 mg for 14 consecutive
days (mLDAC) [21].
Patients who achieved complete remission (CR) received more than
course of 1 consolidation chemotherapy until suitable matched related or
unrelated donor was available for allogeneic (allo)-HSCT. Our standard
consolidation chemotherapy consisted of “3 þ 5” mitoxantrone (12 mg/m2
i.v.) plus intermediate-dose ARA-C (1.0 g/m2 i.v.) or IDA (12 mg/m2) plus
intermediate-dose ARA-C, applied alternatively. Fifty patients relapsed or
died during chemotherapy, and 120 patients received ﬁnal treatment (ie,
allo-HSCT, autologous [auto]-HSCT, or at least 2 cycles of consolidation
chemotherapy after induction chemotherapy). Among these 120 patients, 72
(63 in CR, 9 not in CR) had variable allo-HSCT courses. Thirty-six patients
with an available HLA-matched sibling donor and 29 patients with a suitably
matched (<2 allele-mismatched) unrelated donor underwent allo-HSCT.
After 2009, 7 patients received a haploidentical familial mismatched
transplant (FMT).
As a reduced-intensity conditioning regimen, we administered
busulfex 6.4 mg/kg and ﬂudarabine 150 mg/m2 with 400 cGy total body
irradiation (TBI). Our myeloablative conditioning (MAC) regimen includedtype According to the Combination of NCA, MK Status, and NK Mosaicism at
NK Mosaicism () P Value
% n CR, n (%) 3-yr OS, % CR Rate OS
92 39 (42.4) 12 .009* .004*
44 29 (65.9) 21 .060 .058
48 10 (20.8) 0 .056 .026*
51 21 (41.2) 12 .094 .158
41 18 (43.9) 10 .038* .010*
31 7 (22.6) 0 .017* .024*
61 32 (52.5) 19 .101 .030*
18 6 (33.3) 24 .011* .120
49 13 (26.5) 8 .001* .004*
21 3 (14.3) 0 .002* .002*
28 10 (35.7) 14 .046* .195
43 26 (60.5) 17 .783 .104
9 2 (22.2) 0 .608 .356
4 d d d d
7 3 (42.9) 0 .663 .532
16 13 (81.3) 34 .684 .366
6 3 (50) 0 .519 .384
1 d d d d
42 25 (59.6) 17 .540 .126
22 4 (18.2) 0 .007* .001*
ing neutrophils >1000  106/L and platelets >100,000  106/L).
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12.8 mg/kg. For FMT, we used busulfex 6.4 mg/kg, ﬂudarabine 150 mg/m2,
and 800 cGy TBI with antithymocyte globulin (ATG, 1.25 mg/d) for 4 days
[22]. If a patient achieved CR and did not have a suitable donor, we also
considered auto-HSCT in 15 young patients (age <60 yr) with a MAC
regimen consisting of ARA-C 9 g/m2, melphalan 100 mg/m2, and 1200 cGy
TBI [23]. The remaining 33 patients were treated with chemotherapy alone.Statistical Analysis
The purpose of this study was to assess clinical outcomes according to
the stratiﬁcation of adverse-risk karyotype. All categorical variables were
compared using the chi-square test and Fisher’s exact test, and continuous
variables were assessed with the Student t test, Wilcoxon rank-sum test, and
1-way analysis of variance (ANOVA). OS and disease-free survival (DFS) rates
were calculated using the Kaplan-Meier survival method and were limited
to subgroups of at least 5 patients, and log-rank analysis was used to eval-
uate differences aongsubgroups. Survival analyses were performed from the
date of diagnosis for OS and from the date of ﬁrst remission for DFS. For the
patients who underwent HSCT, analysis was performed from the date of
stem cell infusion.
The cumulative incidence of relapse (CIR) was calculated by cumulative
incidence estimates, treating nonrelapse death as a competing risk, and
compared using the Gray test [24]. Univariate and multivariate analyses
using the Cox proportional regression model were used to calculate the
survival hazard ratio (HR). The statistical analyses were performed using SAS
9.2 (SAS Institute, Cary, NC) and R version 2.15.1 (R Foundation for Statistical
Computing, Vienna, Austria). Statistical signiﬁcance was set at P < .05.RESULTS
Clinical Outcomes According to NCA and MK Status
The study cohort comprised 92 patients (43.6%) without
CK and 119 patients (56.4%) with CK (NCA 3), including 73Figure 1. OS and DFS of adverse-risk karyotype AML according to the number of chro
allo-HSCT (B). In the 3 subgroups classiﬁed by NCA, the NCA5 subgroup demonstrat
most prognostic predictive NCA could be determined at the level of 5 in adverse-risk(61.3%) with 5 chromosomal aberrations and 46 (38.7%)
with 3 or 4 aberrations (Table 1). The overall CR rate was
75.3% in patients age <50 yr and 30.1% in elderly patients
(P < .001). The CR rate was 45.4% for NCA 3 versus 61.9%
for NCA <3 (P ¼ .017), 40.0% for NCA 4 versus 62.9% for
NCA <4 (P ¼ .001), 38.4% for NCA 5 versus 60.1% for NCA
<5 (P ¼ .003), and 40.7% for MKþ AML versus 57.2% for non-
MKþ AML (P ¼ .031). CKþMKþ was associated with the
lowest CR rate (39.6%). As a single chromosomal abnor-
mality, inv(3q) or inv(3;3) was associated with the lowest
CR rate (25.0%).
In our comparison of outcomes in the NCA 5 and NCA
3/4 subgroups with those in patients with non-CK adverse-
risk AML (Figure 1); the NCA 5 subgroup had the worst
OS (HR, 1.896; 95% CI, 1.3 to 2.6; P < .001) and DFS (HR,
1.530; 95% CI, 1.1 to 2.1; P ¼ .008). Although the OS and DFS
results were also signiﬁcantly inferior at the cut-off of
NCA3 (P ¼.012 and .043) or 4 (P ¼ .002 and .018), the
statistical value was most signiﬁcant at NCA5. After allo-
HSCT, the trend was consistent, with the worst OS (HR,
1.962; 95% CI, 1.0 to 3.7; P ¼ .038) and DFS (HR, 0.848; 95%
CI, 0.9 to 3.5; P ¼ .055) in the NCA 5 subgroup. Compared
with the NCA 5 subgroup, the NCA <5 subgroup,
including NCA <3 and NCA 3/4, showed signiﬁcant
improvement (by at least 37%) in 5-yr OS and 5-yr DFS
after allo-HSCT. The NCA 3/4 subgroup (n ¼ 46) showed a
trend toward better OS compared with the NCA <3 sub-
group (Figure 1B).mosomal aberrations in all 211 patients (A) and in the patients who underwent
ed the worst outcomes even after treatment with allo-HSCT. In this study, the
karyotype AML.
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(n ¼ 59) had worse OS (P ¼ .041) and DFS (P ¼ .024). Most of
the patients withMK had CK (CKþMKþ; 53 of 59, 89.8%), and
45 of the 53 patients (84.9%) with CKþMKþ had NCA 5.
Only 6 patients (10.2%) hadMK alone (CKMKþ). Among the
152 patients without MK, 66 had CK (CKþMK; 43.4%) and
86 had a single adverse-risk karyotype (CKMK; 56.6%).
Survival outcomes were worse in the CKþMKþ (HR, 1.774;
95% CI, 1.2 to 2.6; P ¼ .004) and the NCA 5 with MKþ (HR,
2.05; 95% CI, 1.4 to 3.0; P < .001) subgroups. After allo-HSCT,
both the MK and non-MK subgroups showed slightly
improved OS and DFS rates, but the non-MK adverse-risk
AML subgroup did not receive a statistically signiﬁcant
beneﬁt from allo-HSCT compared with the MKþ AML sub-
group (P ¼ .204).Clinical Outcomes According to NK Mosaicism
We compared treatment outcomes in terms of CR rate, OS,
and CIR rate after HSCT in several comparative settings ac-
cording to the combined status of NK mosaicism (Table 2).
Among the 211 patients, the 119 (56.4%) with NK mosaicism
showed a signiﬁcantly superior CR rate (60.5%; P¼ .009) with
favorable OS (HR, 0.634; 95% CI, 0.4 to 0.8; P ¼ .004) and DFS
(HR, 0.730; 95% CI, 0.5 to 0.9; P¼ .037) (Figure 2A). Compared
with non-NK mosaicism, NK mosaicism also was associated
with higher CR rates in the NCA 5 (50.0% versus 22.6%;
P ¼ .017) and NCA <5 (66.2% versus 52.5%; P ¼ .101) sub-
groups, with signiﬁcantly superior OS (P ¼ .024 and .030,
respectively). Subgroup analysis of patients with NCA 3 or
MKþ AML showed better CR rates (P ¼ .001 and .007,
respectively) with favorable OS rates (P ¼ .004 and .001,
respectively) when NK mosaicism was combined, and in the
most unfavorable CKþMKþ subgroup, NK mosaicism also
showed higher a CR rate (58.2% versus 14.3%; P ¼ .002), with
signiﬁcantly favorable OS (P ¼ .002) and DFS (P ¼ .001),
compared with non-NK mosaicism (Figure 2B).Table 2
Three-year CIR and OS in Patients Undergoing HSCT According to the Combination
NK Mosaicism (þ)
n 3-yr CIR, % 3-yr OS
Total cohort (n ¼ 87) 51 47 49
Allo-HSCT (n ¼ 72) 46 46 49
Auto-HSCT (n ¼ 15) 5 100 0
Age (median, 37 yr; range, 15-63 yr)
<37 yr (n ¼ 43) 26 41 54
37 yr (n ¼ 44) 25 69 39
Sex
Male (n ¼ 47) 29 56 42
Female (n ¼ 40) 22 34 59
Karyotype subgroup
NCA 5 (n ¼ 22) 16 63 22
NCA <5 (n ¼ 65) 35 40 61
NCA 3/4 (n ¼ 18) 13 66 71
NCA 3 (n ¼ 40) 29 67 44
CKþMKþ (n ¼ 13) 11 73 42
CKþMK (n ¼ 27) 18 75 46
NCA <3 (n ¼ 47) 22 16 55
Inv(3), t(3;3) (n ¼ 5) 2 d d
Abnormal 5q/5 (n ¼ 4) 2 d d
Abnormal 7q/7 (n ¼ 8) 6 18 40
11q23 (n ¼ 21) 7 17 71
t(6;9) (n ¼ 8) 5 100 60
CK MKþ (n ¼ 3) 2 d d
CK MK (n ¼ 44) 20 14 64
MKþ (total, n ¼ 16) 13 73 34
* P < .05.After HSCT, patients with NK mosaicism also had a more
favorable 3-year OS (49% versus 25%; P ¼ .060), with a
signiﬁcantly lower CIR rate (47% versus 81%; P ¼ .008). A
favorable effect of NK mosaicismwas not seen in the NCA5
subgroup after HSCT; however, in the NCA <5 subgroup, NK
mosaicism was associated with signiﬁcantly superior OS
(P ¼ .011) and lower CIR rate (P ¼ .008) even after HSCT. NK
mosaicism also was associated with favorable OS in the NCA
<3 subgroup (P ¼ .035) after HSCT (Table 2).Clinical Outcomes According to Combinatorial Analysis
Based on the foregoing results, we then divided the pa-
tients into 4 subgroups according to the combination of NCA
and NK mosaicism: subgroup 1, NCA <5 with NK mosaicism;
subgroup 2, NCA <5 without NK mosaicism; subgroup 3,
NCA 5 with NK mosaicism; and subgroup 4, NCA 5
without NKmosaicism (Table 3). The average patient agewas
signiﬁcantly older in subgroup 4 (median age, 60 yr; range,
19-85 yr; P < .001). The proportion of MK was signiﬁcantly
higher in subgroups 3 and 4. Other factors did not differ
signiﬁcantly among the 4 subgroups, except for age and MK
status. Among the 170 patients who underwent remission-
induction chemotherapy, 111 (65.3%) achieved CR, with the
highest CR rate in subgroup 1 (77.2%; P ¼ .010). In the pa-
tients age <60 yr, subgroup 1 also had the highest CR rate
(81.5%; P ¼ .050), and subgroup 4 had the lowest CR rate
(46.2%). In both patients who received MAC chemotherapy
and those who received reduced-intensity chemotherapy,
subgroup 1 had the highest CR rates (75.0% and 100%,
respectively) and subgroup 4 had the lowest CR rates (50.0%;
P ¼ .046 and 14.3%; P ¼ .018, respectively). The 2 NCA 5
subgroups, with signiﬁcantly older patients, received a
greater proportion of reduced-intensity chemotherapy
(n ¼ 14; 26.9%; P ¼ .003) and experienced more relapses
after remission (n ¼ 11; 41.4%; P ¼ .046). However, our risk-
adapted treatment strategy showed no signiﬁcant differenceof NCA, MK Status, and NK Mosaicism at Diagnosis
NK Mosaicism () P Value
, % n 3-yr CIR, % 3-yr OS, % CIR OS
36 81 25 .008* .060
26 79 27 .021* .160
10 86 20 .490 .569
17 83 24 .007* .021*
19 79 28 .384 .842
18 76 25 .612 .537
18 74 24 .002* .055
6 100 0 .196 .809
30 77 30 .008* .011*
5 60 60 .867 .454
11 79 27 .273 .580
2 d d d d
9 78 33 .336 .795
25 79 24 .004* .035*
3 d d d d
2 d d d d
2 d d d d
14 72 38 .126 .281
3 d d d d
1 dd d d dd
24 81 25 .003* .029*
3 d d d d
Figure 2. (A) NK mosaicism in combination with an adverse-risk karyotype was associated with signiﬁcantly superior OS and DFS on multivariate analysis (with
variables including age, sex, abnormal chromosomal aberrations, and initial treatment). (B) In the CKþMKþ subgroup, NK mosaicism was associated with signiﬁcantly
favorable OS and DFS compared with no NK mosaicism.
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Baseline characteristics of the 4 subgroups are displayed in
Table 3, with survival outcomes compared separately in the
entire patient group and in the patients who underwent allo-
HSCT.
In analysis of the entire group, subgroup 4 had the worst
OS (HR, 3.2; 95% CI, 2.0 to 5.1; P< .001) and DFS (HR, 2.3; 95%
CI, 1.4 to 3.6; P < .001), and subgroup 1 had the best OS (HR,
0.431; 95% CI, 0.3 to 0.6; P< .001) and DFS (HR, 0.590; 95% CI,
0.4 to 0.8; P ¼ .004) (Figure 3A). After allo-HSCT, subgroup 4
had the worst survival outcomes, and subgroup 1 achieved
the most signiﬁcant improvement in survival outcomes after
allo-HSCT, with superior OS (HR, 0.293; 95% CI, 0.1 to 0.6;
P ¼ .002) and a lower CIR rate (HR, 0.259; 95% CI, 0.1 to 0.6;
P ¼ .005) (Figure 3B).
Survival Outcomes of Postremission Treatments and
Multivariate Analysis
Figure 4 shows OS and DFS curves according to post-
remission treatment. As expected, allo-HSCT was associated
with themost favorable outcomes comparedwith auto-HSCT
or chemotherapy alone for adverse-risk karyotype AML.
After adjusting the inﬂuential factors by multivariate
analysis, we found consistent ﬁndings after analysis using
time-dependent Cox-proportional hazard regression in the
patients who underwent postremission treatments (n¼ 120)
and allo-HSCT (n¼ 72). Subgroup 4 showed theworst OS andDFS and higher CIR rate after allo-HSCT compared with the
most favorable subgroup, subgroup 1 (Table 4).
DISCUSSION
Although the diagnosis of adult AML with adverse-risk
karyotype establishes indications for treatment with in-
tensive chemotherapy followed by allo-HSCT for long-term
remission [1,25], overall clinical outcomes remain dismal
owing to high rates of relapse and therapy-related mortality.
Treatment strategies should differ for patients at higher risk
for relapse, but a standard treatment protocol other than
allo-HSCT and early reduction of immunosuppressive agents
has yet to be introduced for these patients. Our study
included 211 adverse-risk patients, 72 of whomwere treated
with allo-HSCT from an available donor. We followed all
patients from diagnosis to their ﬁnal treatments, including
allo-HSCT, auto-HSCT, or consolidation chemotherapy alone.
In this study, patients in subgroup 4 were signiﬁcantly older,
and our risk-adapted treatment strategy reﬂected the difﬁ-
culty in treating these patients. A larger proportion of this
subgroup received attenuated-dose chemotherapy and had a
higher likelihood of relapse, whereas a smaller proportion of
underwent allo-HSCT.
Among patients with AML and an adverse-risk karyotype,
the most signiﬁcant number of abnormal chromosomal ab-
normalities for the prediction of worse survival outcomewas
determined at NCA 5. Many of the previous studies that
Table 3
Multivariate analysis for OS and DFS in the entire patients who underwent post-remission treatments (n¼120), and OS and CIR in the subgroup treated with allo-
HSCT (n¼72).(*p < 0.05)
NCA <5 (n ¼ 138) NCA 5 (n ¼ 73) P Value
NK Mosaicism (þ)
(n ¼ 77)
NK Mosaicism ()
(n ¼ 61)
NK Mosaicism (þ)
(n ¼ 42)
NK Mosaicism ()
(n ¼ 31)
All patients (n ¼ 211)
Age, yr, median (range) 45.21 (18-77) 44.91 (18-75) 50.51 (18-76) 60.02 (19-85) <.001*
Male sex, n (%) 46 (59.7) 33 (54.1) 21 (50.0) 18 (58.1) .755
WBC (106/mL) 15,7701 27,7811 16,6011 21,9411 .237
BM blast (%), median (range) 67.11 (20-98) 61.91 (20-98) 66.91 (21-98) 61.61 (17-98) .570
PB blast (%), median (range) 31.91 (0-97) 37.51 (0-98) 30.71 (0-93) 36.31 (0-97) .537
Platelet (106/mL) 58,5001 54,0001 53,4161 56,0001 .341
MK, n (%) 11 (14.3) 3 (4.9) 26 (61.9) 19 (61.3) <.001*
Treated patients (n ¼ 170), n (%)y 66 (86.7) 52 (85.2) 33 (78.6) 19 (61.3) .022*
Male sex, n (%) 36 (54.5) 27 (51.9) 18 (54.5) 12 (63.2) .871
Age, yr, median (range) 41.51 (18-77) 41.41 (18-74) 46.31 (18-68) 51.52 (19-71) .040*
Age <60 yr, n (%) 54 (81.8) 44 (84.6) 24 (72.7) 13 (68.4) .334
Age 60 yr, n (%) 12 (18.2) 8 (15.4) 9 (27.3) 6 (31.6)
Treatment, n (%)
Intensive chemotherapy 60 (90.9) 49 (94.2) 26 (78.8) 12 (63.2) .003*
Reduced-intensity chemotherapy 6 (9.1) 3 (5.8) 7 (21.2) 7 (36.8)
CR, n (%) 51 (77.2) 32 (61.5) 21 (63.6) 7 (36.8) .010*
Age <60 yr 44 (81.5) 28 (63.6) 16 (66.6) 6 (46.2) .050
Age 60 yr 7 (58.3) 4 (50.0) 5 (55.5) 1 (16.6) .379
Intensive chemotherapy 45 (75.0) 31 (63.3) 18 (69.2) 6 (50.0) .046*
Reduced-intensity chemotherapy 6 (100) 1 (33.3) 3 (42.8) 1 (14.3) .018*
Relapse after CR, n (%) 15 (29.4) 3 (9.4) 9 (42.8) 2 (28.6) .046*
Early death (<8 wk), n (%) 7 (10.6) 8 (15.4) 4 (12.1) 5 (26.3) .365
Loss to follow-up, (%) 5 (7.5) 9 (17.3) 7 (21.2) 5 (26.3) .118
Finally treated patients (n ¼ 120), n (%)z 54 (81.8) 35 (67.3) 22 (66.6) 9 (47.3) .024*
Age, yr, median (range) 39.81 (18-72) 39.91 (18-74) 44.61 (18-65) 44.41 (19-70) .511
Male sex, n (%) 29 (53.7) 18 (51.4) 12 (54.5) 6 (66.7) .878
HSCT (n ¼ 87), n (%) 35 (68.6) 30 (90.9) 16 (72.7) 6 (66.7) d
Allo-HSCT (n ¼ 72), n (%) 30 (85.7) 20 (66.6) 16 (100) 6 (100) d
Non-CR pre-HSCT, n (%) 2 (5.7) 3 (10.0) 2 (12.5) 2 (33.3) .509
MSD allo-HSCT (n ¼ 36), n (%) 17 (56.6) 9 (45.0) 6 (27.3) 4 (66.7) .494
URD þ FMT (n ¼ 36), n (%) 13 (43.4) 11 (55.0) 10 (45.4) 2 (33.3)
MAC regimen, n (%) 24 (80.0) 17 (85.0) 10 (62.5) 3 (50.0) .187
BM as stem cell source, n (%) 19 (63.3) 14 (70.0) 8 (50.0) 2 (33.3) .333
CD34  106/kg, median (range) 5.63 (0.2-34.4) 4.67 (0.4-14.9) 4.81 (1.7-10.2) 5.55 (4.8-15.4) .665
CD3  106/kg, median (range) 182.8 (10.9-701.4) 165.6 (7.0-731.6) 182.8 (7.9-701.4) 165.6 (7.0-731.6) .295
Auto-HSCT (n ¼ 15), n (%) 5 (9.8) 10 (30.3) 0 (0.0) 0 (0.0) d
Non-CR pre-HSCT, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) d
Chemotherapy alone (n ¼ 33), n (%) 19 (31.4) 5 (9.1) 6 (27.3) 3 (33.3) d
Intensive (n ¼ 27), n (%) 17 (27.5) 4 (6.1) 5 (83.3) 1 (33.3) .060
mLDAC (n ¼ 6), n (%) 2 (3.9) 1 (3.0) 1 (16.7) 2 (66.7)
MSD indicates matched sibling donor; URD, unrelated donor.
1,2Different numbers indicate signiﬁcant difference between groups based on Tukey’s multiple-comparison test by ANOVA.
* P < .05.
y Forty-one patients received palliative care only.
z Finally treated patients: Patients who received at least 2 cycles of consolidation after induction chemotherapy or HSCT. Nine patients underwent allo-HSCT
in non-CR. Fifty patients died during induction or loss to follow-up.
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generally acceptable for prediction of poor survival outcome
[1-3,9,17,26]. On the other hand, a recent study identiﬁed the
predictive cutoff as NCA 4 [4] and another identiﬁed NCA
5 as the signiﬁcant cutoff for predicting poor survival
outcome (OS, 5.7 mo), although there were no statistical
differences among the NCA 3, 4, and 5 subgroups [27].
However, in the present study, 73 patients out of 119 with
CKþ AML (61.3%) had NCA 5, and the poor outcome asso-
ciated with CKþ AMLmight be related to theworse prognosis
of patients with NCA5. Furthermore, patients with NCA 3/4
(n¼ 46) showed relatively better OS even comparedwith the
patients with adverse-risk AML with NCA <3. All of our re-
sults were applicable in the allo-HSCT subgroup analysis as
well. These results also support recent Center for Interna-
tional Blood and Marrow Transplant Research data showing
worse outcome in patients with AML with NCA 5 after
HSCT [28].Our present series had relatively few patients with MKþ
AML (n ¼ 59; 3.7%) compared with previous studies
[9-11,27,29-31]. This may reﬂect a genetic variation between
Western and Asian countries and may be related to the
relatively larger proportion of younger patients with AML
(age 30 to 40 yr) in our center and in Korea overall. Although
the number was relatively small, our patients with MKþ AML
showed inferior OS and DFS compared with those with
adverse-risk AML without MK (P ¼ .041), in agreement with
previous studies [9,10]. Our data show that a large proportion
of patients withMKþ AML are also CKþ, especially those with
NCA5; however, OSwas not signiﬁcantly different based on
MK status after allo-HSCT, which might be related to the low
preponderance of MK in this study.
Although our data suggest that the poor prognosis
associated with MKþ AML might be slightly overcome by
allo-HSCT (with an increase in 5-yr OS to 17%), they also
suggest that patients with adverse-risk AML without MK
Figure 3. (A) In analysis of the entire group (n ¼ 211), subgroup 4 (NCA 5 without NK mosaicism; n ¼ 31) showed the worst OS (HR, 3.2; 95% CI, 2.0-5.1; P < .001)
and DFS (HR, 2.3; 95% CI, 1.4-3.6; P < .001), whereas subgroup 1 (NCA <5 with NK mosaicism; n ¼ 77) showed signiﬁcantly superior OS and DFS. (B) In analysis of the
patients who underwent allo-HSCT, subgroup 4 (n ¼ 6) had the worst OS (HR, 3.8; 95% CI, 1.6-8.9; P ¼ .002) and highest CIR rate (HR, 6.3; 95% CI 1.9-20.3; P ¼ .002) of
all the subgroups. In contrast, subgroup 1 (n ¼ 30) showed the most favorable OS with a lower CIR rate after allo-HSCT.
J.-H. Yoon et al. / Biol Blood Marrow Transplant 20 (2014) 80e8886might not receive any signiﬁcant beneﬁt from allo-HSCT.
Previous large studies have shown the inferior OS of MKþ
AML after allo-HSCT; in 1 study, particularly in CKþMKþ, the
prognosis was dismal even after allo-HSCT [30], and others,
patients with MKþ AML demonstrated only limited
improvement in survival after allo-HSCT [31,32]. Middeke
et al. [33] recently analyzed patients with high-risk AMLFigure 4. OS and DFS curves accordinafter allo-HSCT (n ¼ 95) and found no signiﬁcant difference
in OS between the MKþ and MK subgroups, in agreement
with our results. Even though it is awidely accepted adverse
factor for survival outcomes, MKþ AML should be reeval-
uated in larger studies to determine which factor is more
predictive for poor prognosis, MK or CK with NCA 5, or
both.g to postremission treatments.
Table 4
Time-dependent Cox Regression Model was Used for Multivariate OS and DFS Analysis in the Entire Patients Who Underwent Postremission Treatments
(n ¼ 120), and OS and CIR after Allo-HSCT (n ¼ 72) Was Analyzed by Cox-Proportional Hazards Regression Model
Patients Finally Treated (n ¼ 120) Post Allo-HSCT (n ¼ 72)
OS DFS OS CIR
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
NCA and NK mosaicism
NCA <5 with NK mosaicism 1.000 d 1.000 d 1.000 d 1.000 d
NCA 5 with NK mosaicism 1.587 (0.8-3.0) .160 1.344 (0.6-2.8) .431 2.560 (0.9-9.0) .064 1.945 (0.5-6.8) .297
NCA <5 without NK mosaicism 1.684 (0.7-3.7) .196 1.450 (0.8-2.6) .221 2.907 (1.0-6.3) .042* 3.411 (1.2-9.7) .022*
NCA 5 without NK mosaicism 2.537 (1.1-5.8) .030* 2.395 (1.1-5.4) .034* 3.146 (1.2-8.6) .025* 6.184 (1.8-21.4) .004*
Monosomal karyotype 0.942 (0.5-1.9) .869 1.112 (0.6-2.2) .753 1.245 (0.5-2.8) .603 2.035 (0.7-5.5) .166
Age 1.043 (0.6-1.8) .887 1.360 (0.8-2.2) .211 1.308 (0.1-1.8) .832 0.986 (0.9-1.0) .478
Male sex 1.078 (0.6-1.8) .773 1.360 (0.8-2.2) .211 1.528 (0.7-3.1) .246 1.476 (0.6-3.5) .327
Leukocytes 50,000  106/mL 0.842 (0.4-1.8) .662 1.047 (0.5-2.2) .905 1.417 (0.5-3.9) .500 1.562 (0.4-5.6) .497
Postremission treatments
Chemotherapy alone 1.000 d 1.000 d d d d d
Auto-HSCT 0.179 (0.05-0.5) .003* 0.299 (0.1-0.6) .018* d d d d
Allo-HSCT 0.113 (0.02-0.5) .001* 0.254 (0.1-0.8) .002* d d d d
BM as stem cell source d d d d 0.547 (0.2-1.5) .232 0.677 (0.2-1.9) .467
MAC regimen d d d d 1.049 (0.4-2.3) .909 0.367 (0.1-1.5) .161
* P < .05.
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to the ambiguous additional effect in the NCA 5 subgroup,
and divided the patients into 4 subgroups according to NCA
5 and <5 with or without NK mosaicism. We previously
identiﬁed that CK was associated with higher rates of NK
mosaicism (61.7%) compared with other chromosomal ab-
normalities [15]. In the present study, the NCA 3 subgroup
(n ¼ 119) included 70 patients (58.8%) with NK mosaicism
and the NCA 5 subgroup (n ¼ 73) included 42 patients
(57.5%) with NK mosaicism. Similarly, the MK subgroup
(n ¼ 59) included 37 patients (62.7%) with NK mosaicism.
These proportions allowed us to focus on the signiﬁcant ef-
fect of NK mosaicism especially in the MK and CK subgroups.
NK mosaicism in patients with adverse-risk AML was asso-
ciated with a signiﬁcantly higher CR rate and superior OS in
each of the NCA 3, NCA 5, MKþ, and CKþMKþ subgroups.
The CKþMKþ without NK mosaicism (n ¼ 21) and NCA 5
without NKmosaicism (n¼ 31) subgroups demonstrated the
lowest CR rates (14.3% and 22.6%, respectively), with 100%
mortality at the 3-yr follow-up in both subgroups. We
cautiously suggest that this highest-risk AML group might
have intrinsically chemorefractory properties, and thus we
should change our treatment strategy to incorporate earlier
allo-HSCT, after achievement of ﬁrst CR, or to earlier reduc-
tion of immunosuppressive agents with emerging novel
therapeutic options, such as immune cell therapy and vac-
cine trials. In contrast, the NCA<3 with NK (n¼ 49) and NCA
<5 with NK (n ¼ 77) subgroups demonstrated a deﬁnite
survival beneﬁt, particularly after HSCT, with a 3-year OS of
55% (P ¼ .011) and 61% (P ¼ .035), respectively. In these
groups, we should also consider establishing a treatment
strategy other than allo-HSCT. If a donor is not available, then
we may actively consider auto-HSCT or haploidentical FMT
with an expectation of good survival outcome.
The reason for the favorable effect of NK mosaicism in
adverse-risk karyotypes is unclear [13-15]. One hypothesis is
that NKmosaicismmay be associatedwith altered sensitivity
to high-dose chemotherapy. In the adverse-risk karyotype,
for example, blasts with NK mosaicism may be more sensi-
tive to chemotherapy compared with those without NK
mosaicism, andwe can hypothesize that the altered response
to chemotherapy owing to NK mosaicism might be associ-
ated with the onset and clonal evolution of AML or relatedwith their different BM niche. We also hypothesized that a
higher proportion (ie, 4 and 6 normal metaphases out of 20
metaphases; 20% and 30%, respectively) of NK mosaicism
may present more favorable outcomes. Our data show that a
higher proportion of NK mosaicism was associated with
signiﬁcantly more favorable outcomes, but the statistical
values (P ¼ .018 and .014) were similar to that of NK mosai-
cismwith 1 copy of normal metaphase (P ¼ .015). We hope
that further basic studies will be performed based on these
clinical results.
In conclusion, this study shows that patients with
adverse-risk AML can be divided into 2 groups based on a
combination of NCA and NK mosaicism and MK status, a
group that can beneﬁt from allo-HSCT and a group with very
poor prognosis that will receive no survival beneﬁt from allo-
HSCT. Patients with NCA 5 without NK mosaicism can be
stratiﬁed into a very poor prognosis subgroup, but patients
with NCA <5 with NK mosaicism demonstrated a survival
beneﬁt from allo-HSCT. Larger studies are needed to evaluate
the risk stratiﬁcation associated with factors in the allo-HSCT
setting and to identify novel treatment strategies for patients
with AML with very poor prognosis.ACKNOWLEDGMENTS
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